Systematic review of blood biomarkers in cystic fibrosis pulmonary exacerbations

Chest

Volumn 144, Issue 5, 2013, Pages 1659-1670

  Shoki, Alborz Hakimi ^a   Mayer Hamblett, Nicole ^b   Wilcox, Pearce G ^c,d   Sin, Don D ^c,d   Quon, Bradley S ^c,d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c ST PAUL S HOSPITAL   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CALGRANULIN; COLLAGENASE 3; D DIMER; GAMMA INTERFERON; GELATINASE A; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; LACTOFERRIN; LEUKOCYTE ELASTASE; MACROPHAGE ELASTASE; MALONALDEHYDE; MYELOPEROXIDASE; RANTES; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR; TRYPSIN INHIBITOR; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ARTICLE; CYSTIC FIBROSIS; DISEASE ACTIVITY; DISEASE DURATION; DISEASE EXACERBATION; DISEASE MARKER; DISEASE SEVERITY; FORCED VITAL CAPACITY; HUMAN; MORBIDITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN FUNCTION; RECURRENT DISEASE; SYSTEMATIC REVIEW; TREATMENT RESPONSE; VALIDATION STUDY;

EID: 84887447853     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-0693     Document Type: Article

References (64)

1. Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am J Respir Crit Care Med. 1996;154(5):1229-1256.
2. Britto MT, Kotagal UR, Hornung RW, Atherton HD, Tsevat J, Wilmott RW. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest. 2002;121(1):64-72.
3. Robson M, Abbott J, Webb K, Dodd M, Walsworth-Bell J. A cost description of an adult cystic fibrosis unit and cost analyses of different categories of patients. Thorax. 1992;47(9):684-689.
4. Goss CH, Burns JL. Exacerbations in cystic fibrosis. 1: epidemiology and pathogenesis. Thorax. 2007;62(4):360-367.
5. Dakin C, Henry RL, Field P, Morton J. Defining an exacerbation of pulmonary disease in cystic fibrosis. Pediatr Pulmonol 2001;31(6):436-442.
6. Kraynack NC, Gothard MD, Falletta LM, McBride JT. Approach to treating cystic fibrosis pulmonary exacerbations varies widely across US CF care centers. Pediatr Pulmonol 2011;46(9):870-881.
7. Sanders DB, Bittner RC, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med. 2010;182(5):627-632.
8. Ramsey BW, Banks-Schlegel S, Accurso FJ, et al. Future directions in early cystic fibrosis lung disease research: an NHLBI workshop report. Am J Respir Crit Care Med. 2012;185(8):887-892.
9. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264-269, W264.
10. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008- 2012.
11. Taylor G, Stern C, Silverman M, Mearns M. Endotoxaemia in cystic fibrosis: response to antibiotics. Arch Dis Child. 1983;58(10):826-828.
12. Hollsing AE, Lantz B, Bergström K, Malmborg AS, Strandvik B. Granulocyte elastase-alpha 1-antiproteinase complex in cystic fibrosis: sensitive plasma assay for monitoring pulmonary infections. J Pediatr. 1987;111(2):206-211.
13. Glass S, Hayward C, Govan JR. Serum C-reactive protein in assessment of pulmonary exacerbations and antimicrobial therapy in cystic fibrosis. J Pediatr. 1988;113(1pt 1):76-79.
14. Rayner RJ, Wiseman MS, Cordon SM, Norman D, Hiller EJ, Shale DJ. Inflammatory markers in cystic fibrosis. Respir Med. 1991;85(2):139-145.
15. Norman D, Elborn JS, Cordon SM, et al. Plasma tumour necrosis factor alpha in cystic fibrosis. Thorax. 1991;46(2):91-95.
16. Meyer KC, Lewandoski JR, Zimmerman JJ, Nunley D, Calhoun WJ, Dopico GA. Human neutrophil elastase and elastase/alpha 1-antiprotease complex in cystic fibrosis. Comparison with interstitial lung disease and evaluation of the effect of intravenously administered antibiotic therapy. Am Rev Respir Dis. 1991;144(3pt 1):580-585.
17. Valletta EA, Rigo A, Bonazzi L, Zanolla L, Mastella G. Modification of some markers of inflammation during treatment for acute respiratory exacerbation in cystic fibrosis. Acta Paediatr. 1992;81(3):227-230.
18. Elborn JS, Cordon SM, Parker D, Delamere FM, Shale DJ. The host inflammatory response prior to death in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection. Respir Med. 1993;87(8):603-607.
19. Watkin SL, Elborn JS, Cordon SM, Hiller EJ, Shale DJ. C-reactive protein is not a useful indicator of intermittent bacterial colonization in early lung disease of patients with cystic fibrosis. Pediatr Pulmonol. 1994;17(1):6-10.
20. Wilmott RW, Frenzke M, Kociela V, Peng L. Plasma interleukin-1 alpha and beta, tumor necrosis factor-alpha, and lipopolysaccharide concentrations during pulmonary exacerbations of cystic fibrosis. Pediatr Pulmonol. 1994;18(1):21-27.
21. Koller DY, Götz M, Eichler I, Urbanek R. Eosinophilic activation in cystic fibrosis. Thorax. 1994;49(5):496-499.
22. Peckham D, Crouch S, Humphreys H, Lobo B, Tse A, Knox AJ. Effect of antibiotic treatment on inflammatory markers and lung function in cystic fibrosis patients with Pseudomonas cepacia. Thorax. 1994;49(8):803-807.
23. Friesen CA, Wiens LA, Burry VF, Portnoy J, Roberts CC. C-reactive protein in acute pulmonary exacerbations of patients with cystic fibrosis. Pediatr Pulmonol. 1995;20(4):215-219.
24. Koller DY, Götz M, Wojnarowski C, Eichler I. Relationship between disease severity and inflammatory markers in cystic fibrosis. Arch Dis Child. 1996;75(6):498-501.
25. Duggan C, Colin AA, Agil A, Higgins L, Rifai N. Vitamin A status in acute exacerbations of cystic fibrosis. Am J Clin Nutr 1996;64(4):635-639.
26. Nixon LS, Yung B, Bell SC, Elborn JS, Shale DJ. Circulating immunoreactive interleukin-6 in cystic fibrosis. Am J Respir Crit Care Med. 1998;157(6pt 1):1764-1769.
27. De Rose V, Oliva A, Messore B, Grosso B, Mollar C, Pozzi E. Circulating adhesion molecules in cystic fibrosis. Am J Respir Crit Care Med. 1998;157(4pt 1):1234-1239.
28. McGrath LT, Mallon P, Dowey L, et al. Oxidative stress during acute respiratory exacerbations in cystic fibrosis. Thorax 1999;54(6):518-523.
29. Range SP, Dunster C, Knox AJ, Kelly FJ. Treatment of pulmonary exacerbations of cystic fibrosis leads to improved antioxidant status. Eur Respir J. 1999;13(3):560-564.
30. Abou-Hatab K, Nixon LS, O'Mahony MS, et al. Plasma esterases in cystic fibrosis: the impact of a respiratory exacerbation and its treatment. Eur J Clin Pharmacol. 1999;54(12):937-941.
31. Wolter JM, Rodwell RL, Bowler SD, McCormack JG. Cytok ines and inflammatory mediators do not indicate acute infection in cystic fibrosis. Clin Diagn Lab Immunol. 1999;6(2):260-265.
32. Eichler I, Nilsson M, Rath R, Enander I, Venge P, Koller DY. Human neutrophil lipocalin, a highly specific marker for acute exacerbation in cystic fibrosis. Eur Respir J. 1999;14(5):1145-1149.
33. Hendry J, Elborn JS, Nixon L, Shale DJ, Webb AK. Cystic fibrosis: inflammatory response to infection with Burkholderia cepacia and Pseudomonas aeruginosa. Eur Respir J. 1999;14(2):435-438.
34. Aris RM, Stephens AR, Ontjes DA, et al. Adverse alterations in bone metabolism are associated with lung infection in adults with cystic fibrosis. Am J Respir Crit Care Med 2000;162(5):1674-1678.
35. Ionescu AA, Nixon LS, Evans WD, et al. Bone density, body composition, and inflammatory status in cystic fibrosis. Am J Respir Crit Care Med. 2000;162(3pt 1):789-794.
36. McColley SA, Stellmach V, Boas SR, Jain M, Crawford SE. Serum vascular endothelial growth factor is elevated in cystic fibrosis and decreases with treatment of acute pulmonary exacerbation. Am J Respir Crit Care Med. 2000;161(6):1877-1880.
37. Bell SC, Bowerman AM, Nixon LE, Macdonald IA, Elborn JS, Shale DJ. Metabolic and inflammatory responses to pulmonary exacerbation in adults with cystic fibrosis. Eur J Clin Invest. 2000;30(6):553-559.
38. Lands LC, Grey VL, Grenier C. Total plasma antioxidant capacity in cystic fibrosis. Pediatr Pulmonol. 2000;29(2):81-87.
39. Shmarina GV, Pukhalsky AL, Kokarovtseva SN, et al. Improvement of nutrient absorption may enhance systemic oxidative stress in cystic fibrosis patients. Mediators Inflamm. 2001;10(2):61-67.
40. Bradley J, McAlister O, Elborn S. Pulmonary function, inflammation, exercise capacity and quality of life in cystic fibrosis. Eur Respir J. 2001;17(4):712-715.
41. Wood LG, Fitzgerald DA, Gibson PG, Cooper DM, Garg ML. Increased plasma fatty acid concentrations after respiratory exacerbations are associated with elevated oxidative stress in cystic fibrosis patients. Am J Clin Nutr. 2002;75(4):668-675.
42. Foell D, Seeliger S, Vogl T, et al. Expression of S100A12 (EN-RAGE) in cystic fibrosis. Thorax. 2003;58(7):613-617.
43. Lagrange-Puget M, Durieu I, Ecochard R, et al. Longitudinal study of oxidative status in 312 cystic fibrosis patients in stable state and during bronchial exacerbation. Pediatr Pulmonol 2004;38(1):43-49.
44. Colombo C, Costantini D, Rocchi A, et al. Cytokine levels in sputum of cystic fibrosis patients before and after antibiotic therapy. Pediatr Pulmonol. 2005;40(1):15-21.
45. Smith JA, Owen EC, Jones AM, Dodd ME, Webb AK, Woodcock A. Objective measurement of cough during pulmonary exacerbations in adults with cystic fibrosis. Thorax 2006;61(5):425-429.
46. Downey DG, Martin SL, Dempster M, et al. The relationship of clinical and inflammatory markers to outcome in stable patients with cystic fibrosis. Pediatr Pulmonol. 2007;42(3):216-220.
47. Kohlhoff SA, Köhler E, Sollich V. Serum myeloperoxidase in cystic fibrosis patients receiving systemic antibiotics. Scand J Infect Dis. 2007;39(2):163-166.
48. Clifton IJ, Kastelik JA, Peckham DG, et al. Ten years of viral and non-bacterial serology in adults with cystic fibrosis. Epidemiol Infect. 2008;136(1):128-134.
49. Latzin P, Fehling M, Bauernfeind A, Reinhardt D, Kappler M, Griese M. Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis. J Cyst Fibros. 2008;7(2):142-146.
50. Saavedra MT, Hughes GJ, Sanders LA, et al. Circulating RNA transcripts identify therapeutic response in cystic fibrosis lung disease. Am J Respir Crit Care Med. 2008;178(9):929-938.
51. Laguna TA, Wagner BD, Luckey HK, et al. Sputum desmosine during hospital admission for pulmonary exacerbation in cystic fibrosis. Chest. 2009;136(6):1561-1568.
52. Roderfeld M, Rath T, Schulz R, et al. Serum matrix metalloproteinases in adult CF patients: Relation to pulmonary exacerbation. J Cyst Fibros. 2009;8(5):338-347.
53. Davidson SJ, Paramothayan S, Hodson ME. Adult cystic fibrosis patients with and without infective exacerbations and their factor XII levels. Blood Coagul Fibrinolysis. 2009;20(6):400-402.
54. Proesmans M, Heyns L, Moons P, Havermans T, De Boeck K. Real life evaluation of intravenous antibiotic treatment in a paediatric cystic fibrosis centre: outcome of home therapy is not inferior. Respir Med. 2009;103(2):244-250.
55. Gray RD, Imrie M, Boyd AC, Porteous D, Innes JA, Greening AP. Sputum and serum calprotectin are useful biomarkers during CF exacerbation. J Cyst Fibros. 2010;9(3):193-198.
56. Shead EF, Haworth CS, Barker H, Bilton D, Compston JE. Osteoclast function, bone turnover and inflammatory cytokines during infective exacerbations of cystic fibrosis. J Cyst Fibros. 2010;9(2):93-98.
57. Harris WT, Muhlebach MS, Oster RA, Knowles MR, Clancy JP, Noah TL. Plasma TGF-b in pediatric cystic fibrosis: Potential biomarker of lung disease and response to therapy. Pediatr Pulmonol. 2011;46(7):688-695.
58. Louw JJ, Toelen J, Proesmans M, Vermeulen F, Billen J, De Boeck K. Serum procalcitonin is not an early marker of pulmonary exacerbation in children with cystic fibrosis. Eur J Pediatr. 2012;171(1):139-142.
59. Sequeiros IM, Jarad NA. Extending the course of intravenous antibiotics in adult patients with cystic fibrosis with acute pulmonary exacerbations. Chron Respir Dis. 2012;9(4):213-220.
60. Sequeiros IM, Jarad N. Factors associated with a shorter time until the next pulmonary exacerbation in adult patients with cystic fibrosis. Chron Respir Dis. 2012;9(1):9-16.
61. Mayer-Hamblett N, Ramsey BW, Kronmal RA. Advancing outcome measures for the new era of drug development in cystic fibrosis. Proc Am Thorac Soc. 2007;4(4):370-377.
62. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111(12):1805-1812.
63. Micheel C M N S, Omenn GS. Evolution of Translational Omics: Lessons Learned and the Path Forward. Washington, DC: The National Academies Press; 2012.
64. Sagel SD, Chmiel JF, Konstan MW. Sputum biomarkers of inflammation in cystic fibrosis lung disease. Proc Am Thorac Soc. 2007;4(4):406-417.